Optimizing Vancomycin Exposure for Early Treatment Response in Very-Low-Birth-Weight Neonates With Late-Onset Sepsis

Area of Science:

• Neonatal Pharmacology
• Infectious Diseases
• Critical Care Medicine

Background:

• Vancomycin is a cornerstone treatment for neonatal late-onset sepsis (LOS).
• Optimal pharmacokinetic/pharmacodynamic (PK/PD) targets for vancomycin in very low birth weight (VLBW) neonates are not well-established.
• Defining effective vancomycin exposure is crucial for improving outcomes in this vulnerable population.

Purpose of the Study:

• To identify vancomycin exposure thresholds associated with early clinical and microbiological effectiveness in VLBW neonates diagnosed with LOS.
• To compare the predictive performance of different vancomycin exposure metrics for treatment success.

Main Methods:

• A multicenter observational study involving VLBW neonates treated for LOS with vancomycin.
• Categorization of patients into early clinical and microbiological cure (ECMC) and late cure groups based on 72-hour outcomes.
• Classification and regression tree analysis and receiver operating characteristic (ROC) curve analysis to determine optimal vancomycin exposure thresholds.

Main Results:

• Thirty-six VLBW neonates with Gram-positive LOS were analyzed; 75% achieved ECMC.
• A significant correlation was found between 24-hour area under the curve (AUC24) and trough concentrations (R²=0.568, P<0.001).
• An AUC24/MIC threshold of ≥253 mg·h/L demonstrated superior discriminative performance for ECMC compared to trough concentrations (AUC-ROC: 0.813 vs. 0.726).

Conclusions:

• Vancomycin AUC24/MIC ≥253 mg·h/L is a superior predictor of early treatment success in VLBW neonates with LOS compared to trough concentrations.
• Both AUC24 and trough concentrations were significantly higher in neonates achieving early cure.
• Prospective validation in larger cohorts is recommended to confirm these findings.